$43.04
1.03% day before yesterday
Nasdaq, May 30, 10:06 pm CET
ISIN
US30161Q1040
Symbol
EXEL

Exelixis, Inc. Stock price

$43.04
+3.89 9.94% 1M
+7.45 20.93% 6M
+9.74 29.25% YTD
+22.26 107.12% 1Y
+24.64 133.91% 3Y
+18.91 78.33% 5Y
+39.60 1,151.16% 10Y
Nasdaq, Closing price Fri, May 30 2025
+0.44 1.03%
ISIN
US30161Q1040
Symbol
EXEL
Sector
Industry

Key metrics

Market capitalization $11.74b
Enterprise Value $10.71b
P/E (TTM) P/E ratio 19.30
EV/FCF (TTM) EV/FCF 13.04
EV/Sales (TTM) EV/Sales 4.66
P/S ratio (TTM) P/S ratio 5.11
P/B ratio (TTM) P/B ratio 5.55
Revenue growth (TTM) Revenue growth 24.50%
Revenue (TTM) Revenue $2.30b
EBIT (operating result TTM) EBIT $814.51m
Free Cash Flow (TTM) Free Cash Flow $820.89m
Cash position $1.03b
EPS (TTM) EPS $2.23
P/E forward 16.64
P/S forward 4.53
EV/Sales forward 4.14
Short interest 9.42%
Show more

Is Exelixis, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Exelixis, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Exelixis, Inc. forecast:

11x Buy
55%
9x Hold
45%

Analyst Opinions

20 Analysts have issued a Exelixis, Inc. forecast:

Buy
55%
Hold
45%

Financial data from Exelixis, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Apr '25
+/-
%
2,299 2,299
24% 24%
100%
- Direct Costs 74 74
7% 7%
3%
2,225 2,225
26% 26%
97%
- Selling and Administrative Expenses 515 515
2% 2%
22%
- Research and Development Expense 895 895
14% 14%
39%
844 844
268% 268%
37%
- Depreciation and Amortization 30 30
18% 18%
1%
EBIT (Operating Income) EBIT 815 815
299% 299%
35%
Net Profit 644 644
214% 214%
28%

In millions USD.

Don't miss a Thing! We will send you all news about Exelixis, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Exelixis, Inc. Stock News

Positive
The Motley Fool
2 days ago
When investing on a budget, buying fractional shares of top companies is one option. Another is to find stocks with relatively affordable price tags per share.
Positive
FXEmpire
9 days ago
Shares of Exelixis, Inc. (EXEL), an oncology-focused biopharmaceutical firm, boosted by Big Money inflows.
Neutral
Business Wire
10 days ago
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from an expansion cohort of the phase 1b/2 STELLAR-002 trial evaluating zanzalintinib in combination with either nivolumab (Opdivo®) or a fixed-dose combination of nivolumab and relatlimab (Opdualag™) in patients with previously untreated advanced clear cell renal cell carcinoma (RCC). These findings, as wel...
More Exelixis, Inc. News

Company Profile

Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.

Head office United States
CEO Michael Morrissey
Employees 1,147
Founded 1994
Website www.exelixis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today